IL235767A - Preserved pyrolidines, pharmaceuticals containing them and their uses - Google Patents

Preserved pyrolidines, pharmaceuticals containing them and their uses

Info

Publication number
IL235767A
IL235767A IL235767A IL23576714A IL235767A IL 235767 A IL235767 A IL 235767A IL 235767 A IL235767 A IL 235767A IL 23576714 A IL23576714 A IL 23576714A IL 235767 A IL235767 A IL 235767A
Authority
IL
Israel
Prior art keywords
same
pharmaceutical compositions
substituted pyrrolidines
pyrrolidines
substituted
Prior art date
Application number
IL235767A
Other languages
English (en)
Hebrew (he)
Other versions
IL235767A0 (en
Original Assignee
Ono Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co filed Critical Ono Pharmaceutical Co
Publication of IL235767A0 publication Critical patent/IL235767A0/en
Publication of IL235767A publication Critical patent/IL235767A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/50—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
IL235767A 2012-05-24 2014-11-18 Preserved pyrolidines, pharmaceuticals containing them and their uses IL235767A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1209138.5A GB201209138D0 (en) 2012-05-24 2012-05-24 Compounds
PCT/EP2013/060650 WO2013174937A1 (en) 2012-05-24 2013-05-23 Substituted pyrrolidines as factor xia inhibitors for the treatment thromboembolic diseases

Publications (2)

Publication Number Publication Date
IL235767A0 IL235767A0 (en) 2015-02-01
IL235767A true IL235767A (en) 2016-09-29

Family

ID=46546584

Family Applications (1)

Application Number Title Priority Date Filing Date
IL235767A IL235767A (en) 2012-05-24 2014-11-18 Preserved pyrolidines, pharmaceuticals containing them and their uses

Country Status (23)

Country Link
US (5) US9394250B2 (OSRAM)
EP (2) EP3056493B1 (OSRAM)
JP (2) JP6142919B2 (OSRAM)
KR (1) KR102090780B1 (OSRAM)
CN (1) CN104379576B (OSRAM)
AU (1) AU2013265256B2 (OSRAM)
BR (1) BR112014027236A2 (OSRAM)
CA (1) CA2874106C (OSRAM)
DK (1) DK2855452T3 (OSRAM)
ES (2) ES2637655T3 (OSRAM)
GB (1) GB201209138D0 (OSRAM)
HU (1) HUE034856T2 (OSRAM)
IL (1) IL235767A (OSRAM)
MX (1) MX363043B (OSRAM)
NZ (1) NZ702070A (OSRAM)
PH (1) PH12014502573A1 (OSRAM)
PL (1) PL2855452T3 (OSRAM)
PT (1) PT2855452T (OSRAM)
RU (1) RU2636050C2 (OSRAM)
SG (1) SG11201408271VA (OSRAM)
TW (1) TWI573786B (OSRAM)
WO (1) WO2013174937A1 (OSRAM)
ZA (1) ZA201408593B (OSRAM)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011100401A1 (en) 2010-02-11 2011-08-18 Bristol-Myers Squibb Company Macrocycles as factor xia inhibitors
PH12014500625B1 (en) 2011-10-14 2018-12-12 Bristol Myers Squibb Co Substituted tetrahydroisoquinoline compounds as factor xia inhibitors
GB201209138D0 (en) * 2012-05-24 2012-07-04 Ono Pharmaceutical Co Compounds
US9758480B2 (en) 2012-07-19 2017-09-12 Sumitomo Dainippon Pharma Co., Ltd. 1-(cycloalkyl-carbonyl)proline derivative
HRP20161378T1 (hr) 2012-08-03 2016-12-02 Bristol-Myers Squibb Company Dihidropiridon kao faktor xia inhibitora
HUE032622T2 (en) 2012-08-03 2017-10-30 Bristol Myers Squibb Co Dihydropyridone p1 as factor xia inhibitors
EP2906541B1 (en) 2012-10-12 2017-11-22 Bristol-Myers Squibb Company Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
MX351848B (es) 2012-10-12 2017-10-31 Bristol Myers Squibb Co Formas cristalinas de inhibidor del factor xia.
WO2014059202A1 (en) 2012-10-12 2014-04-17 Bristol-Myers Squibb Company Guanidine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
WO2014160668A1 (en) 2013-03-25 2014-10-02 Bristol-Myers Squibb Company Tetrahydroisoquinolines containing substituted azoles as factor xia inhibitors
JP6337750B2 (ja) * 2013-11-22 2018-06-06 小野薬品工業株式会社 化合物
CA2939326A1 (en) 2014-01-14 2015-07-23 Sumitomo Dainippon Pharma Co., Ltd. Condensed 5-oxazolidinone derivative
NO2760821T3 (OSRAM) 2014-01-31 2018-03-10
SG10201908467RA (en) 2014-01-31 2019-10-30 Bristol Myers Squibb Co Macrocycles with hetrocyclic p2' groups as factor xia inhibitors
WO2016036893A1 (en) 2014-09-04 2016-03-10 Bristol-Myers Squibb Company Diamide macrocycles that are fxia inhibitors
US9453018B2 (en) 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
AR105646A1 (es) * 2015-08-11 2017-10-25 Actelion Pharmaceuticals Ltd Agentes antibacterianos de 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona sustituida
EP3371162B1 (en) 2015-10-29 2022-01-26 Merck Sharp & Dohme Corp. Macrocyclic spirocarbamate derivatives as factor xia inhibitors, pharmaceutically acceptable compositions and their use
WO2017123518A1 (en) * 2016-01-11 2017-07-20 The Rockefeller University Aminotriazole immunomodulators for treating autoimmune diseases
GB201608453D0 (en) * 2016-05-13 2016-06-29 Univ Liverpool Muscle regeneration
WO2018039094A1 (en) 2016-08-22 2018-03-01 Merck Sharp & Dohme Corp. Pyridine-1-oxide derivatives and their use as factor xia inhibitors
JP7210540B2 (ja) 2017-08-04 2023-01-23 武田薬品工業株式会社 血漿カリクレインの阻害剤およびその使用
CN110240591A (zh) * 2018-03-08 2019-09-17 天津药物研究院有限公司 脯氨酸衍生物及其制备方法和用途
JPWO2020059812A1 (ja) 2018-09-20 2021-08-30 小野薬品工業株式会社 ４−（｛（４ｓ）−１−（４−カルバムイミドイルベンゾイル）−４−［４−（メチルスルホニル）ピペラジン−１−イル］−ｌ−プロリル｝アミノ）安息香酸の新規塩およびその新規結晶形
US11918570B2 (en) 2020-04-13 2024-03-05 The Research Foundation For The State University Of New York Method of treatment for prevention of glucocorticoid toxicity and/or enhancement of muscle regeneration via neutrophil elastase inhibition
CN112915106A (zh) * 2021-02-05 2021-06-08 张虎山 一种肿瘤免疫微环境调控剂的制备及其应用
CN114507245B (zh) * 2022-02-23 2024-03-19 江苏丽源医药有限公司 一种伊多塞班及其中间体的制备方法
CN115010638B (zh) * 2022-05-09 2024-02-13 杭州国瑞生物科技有限公司 一种奈玛特韦中间体的合成方法
WO2025054361A1 (en) * 2023-09-05 2025-03-13 Apellis Pharmaceuticals, Inc. Complement inhibition

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA951618B (en) 1994-03-04 1996-08-27 Lilly Co Eli Antithrombotic agents
WO2002037937A2 (en) 2000-11-07 2002-05-16 Bristol-Myers Squibb Company Acid derivatives useful as serine protease inhibitors
CN1809346A (zh) * 2003-06-18 2006-07-26 默克专利股份公司 作为凝血因子xa和viia的抑制剂用于治疗形成血栓的1－[(4－乙炔基苯基) ]－2－[(苯基)]－吡咯烷－1,2－二酰胺衍生物
US7453002B2 (en) * 2004-06-15 2008-11-18 Bristol-Myers Squibb Company Five-membered heterocycles useful as serine protease inhibitors
EA014245B1 (ru) 2005-12-14 2010-10-29 Бристол-Маерс Сквибб Компани Аналоги арилпропионамида, арилакриламида, арилпропинамида или арилметилмочевины в качестве ингибиторов фактора xia
JP5263686B2 (ja) * 2006-05-16 2013-08-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 置換プロリンアミド、その製造及び薬物としての使用
CN101500993A (zh) * 2006-06-08 2009-08-05 百时美施贵宝公司 作为凝血因子Ⅶa抑制剂用作抗凝血药的2-氨基羰基苯基氨基-2-苯基乙酰胺
TW200827368A (en) 2006-11-21 2008-07-01 Genelabs Tech Inc Amido anti-viral compounds
ES2546815T3 (es) 2006-12-15 2015-09-28 Bristol-Myers Squibb Company Análogos de arilpropilamida, arilacrilamida, arilpropinamida o arilmetilurea como inhibidores del factor XIa
EP2099783A1 (en) * 2006-12-20 2009-09-16 Brystol-Myers Squibb Company Bicyclic lactam factor viia inhibitors useful as anticoagulants
PE20091002A1 (es) * 2007-06-13 2009-07-15 Bristol Myers Squibb Co Analogos dipeptidos como inhibidores del factor de coagulacion
WO2009114677A1 (en) * 2008-03-13 2009-09-17 Bristol-Myers Squibb Company Pyridazine derivatives as factor xia inhibitors
TW201011006A (en) * 2008-06-16 2010-03-16 Nuevolution As IAP binding compounds
USRE48334E1 (en) 2008-09-19 2020-12-01 Takeda Pharmaceutical Company Limited Nitrogen-containing heterocyclic compound and use of same
AU2009305624A1 (en) 2008-10-17 2010-04-22 Exelixis, Inc. Sphingosine-1-phosphate receptor antagonists
GB201209138D0 (en) * 2012-05-24 2012-07-04 Ono Pharmaceutical Co Compounds

Also Published As

Publication number Publication date
US20190263795A1 (en) 2019-08-29
PH12014502573B1 (en) 2015-01-21
JP2015517557A (ja) 2015-06-22
PT2855452T (pt) 2017-06-22
RU2014152276A (ru) 2016-07-20
EP3056493B1 (en) 2017-07-12
PL2855452T3 (pl) 2017-08-31
US10882855B2 (en) 2021-01-05
MX363043B (es) 2019-03-06
HUE034856T2 (en) 2018-03-28
AU2013265256A1 (en) 2014-12-04
US20150152048A1 (en) 2015-06-04
EP2855452A1 (en) 2015-04-08
TW201400454A (zh) 2014-01-01
BR112014027236A2 (pt) 2017-06-27
US9585881B2 (en) 2017-03-07
EP2855452B1 (en) 2017-04-26
US9394250B2 (en) 2016-07-19
IL235767A0 (en) 2015-02-01
DK2855452T3 (en) 2017-07-03
AU2013265256B2 (en) 2017-02-23
US10336741B2 (en) 2019-07-02
ES2628003T3 (es) 2017-08-01
CA2874106A1 (en) 2013-11-28
SG11201408271VA (en) 2015-01-29
US20170137412A1 (en) 2017-05-18
PH12014502573A1 (en) 2015-01-21
CN104379576B (zh) 2017-05-10
WO2013174937A1 (en) 2013-11-28
JP2017160245A (ja) 2017-09-14
CN104379576A (zh) 2015-02-25
KR102090780B1 (ko) 2020-03-18
RU2636050C2 (ru) 2017-11-20
ZA201408593B (en) 2015-08-26
ES2637655T3 (es) 2017-10-16
CA2874106C (en) 2020-05-12
MX2014014246A (es) 2015-02-17
US20160287582A1 (en) 2016-10-06
TWI573786B (zh) 2017-03-11
JP6399148B2 (ja) 2018-10-03
NZ702070A (en) 2016-01-29
JP6142919B2 (ja) 2017-06-07
HK1207854A1 (en) 2016-02-12
EP3056493A1 (en) 2016-08-17
KR20150018788A (ko) 2015-02-24
GB201209138D0 (en) 2012-07-04
US20210147403A1 (en) 2021-05-20

Similar Documents

Publication Publication Date Title
IL235767A (en) Preserved pyrolidines, pharmaceuticals containing them and their uses
IL285390A (en) Arylquinazolines, their preparation and pharmaceutical preparations containing them
IL233154A (en) Compounds, pharmaceuticals containing them and their uses
IL233863A (en) Pyridine derivatives, preparations containing them and their uses
IL234014A0 (en) Cycloalkane derivatives, preparations containing them and their uses
IL238958A0 (en) Glutamase inhibitors, preparations containing them and their uses
IL238959A (en) Glutamase suppressors, preparations containing them and their uses
IL228322A0 (en) History of dispiropyrrolidine, preparations containing them and their uses
IL236057B (en) History of 4,2,1-triazine-6-carboxamide and pharmaceutical preparations containing them
IL235004A0 (en) Antibodies against fgfr2, preparations containing them and their uses
IL237068A (en) 1,3-dioxanomorphides and 1,3-dioxanocodides
IL235585B (en) Substances that bind to ha, preparations containing them and their uses
ZA201501930B (en) Pharmaceutical composition
ZA201509307B (en) Pharmaceutical composition, preparation and uses thereof
IL233824A (en) Compounds 1h - Indazole - 3 - Carboxamide, preparations containing them and their use
EP2832730A4 (en) MIRABEGRAPHIC PHARMACEUTICAL COMPOSITION
ZA201505318B (en) 2-substituted-6-biarylmethylamino-9-cyclopentyl-9h-purine derivatives, use thereof as medicaments, and pharmaceutical compositions
IL236712A0 (en) Di-teri-heteroaryl derivatives, preparations containing them and their uses
IL223405B (en) Phosphoplatins, preparations containing them and their uses
IL233825A (en) H1-indazole-3-carboxamide compounds, preparations containing them and their use in the preparation of medicines
IL232061A (en) The heterocyclic compound in the bicycle, a pharmaceutical product containing it and its use
IL238851A0 (en) The history of pyrrolidine, pharmaceutical preparations and their uses
IL237542B (en) Amphiphilic compounds, their preparations and uses
TWI562776B (en) Pharmaceutical composition and uses thereof
PT2899198T (pt) Péptido sintético pntx(19), composições farmacêuticas e utilização

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed